Please assess the completion status of the following clinical trial:

Trial Title: Cetuximab + Gemox in Biliary Tract Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* histologically or cytologically proven unresectable advanced or metastatic biliary tract cancer (including intrahepatic and extrahepatic CC and gallbladder cancer)~* age ≥ 18 years~* ECOG performance status ≤ 2~* bidimensionally measurable disease per RECIST criteria~* no prior chemotherapy or targeted therapy for advanced disease~* adequate bone marrow reserve (neutrophil count \> 1500 /µL, platelet count \> 100,000 /µL)~* adequate renal function (serum creatinine ≤ 1.5 x the upper limit of normal)~* adequate hepatic function (serum bilirubin \<2.5 x the upper limit of normal (ULN) and serum transaminase level of ≤ 5 x ULN)~* written informed consent~Exclusion Criteria:~* prior palliative treatment~* resectable disease~* brain metastases~* serious or uncontrolled concurrent medical illness~* pregnancy or nursing~* history of other malignancies with the exception of excised cervical or basal skin/squamous cell carcinoma~* peripheral neuropathy (grade \> 1)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).